Adalimumab and Antidrug Antibodies in Plaque Psoriasis Patients
A study published in late 2013 indicated that there is strong correlation between adalimumab and antidrug antibody (ADA) formation in plaque psorasis patients. The antibodies affect clinical response of adalimumab, a human monoclonial immunoglobulin G1 antibody and tumor necrosis factor antagonist.
The study recently published was an extension of an earlier study that had looked at 29 plaque psoriasis patients followed up for 24 weeks. The cohort extended to 80 patients and the follow-up time to one year.
The 80 psoriasis patients were treated with adalimumab. The disease severity was assessed and blood samples were taken. At baseline and weeks 12, 24, and 52, the adalimumab and ADA concentrations were ascertained. By week 24, 90% of the cohort displayed ADA formation. The study further supported that there is a strong correlation between adalimumab and ADA formation.
In order in control bias in the study, the assessors of patients’ Psoriasis Area and Severity Index (PASI) were not made aware of the presence of adalimumab or serum concentration in each case. Nor were those looking at serum samples made aware of PASI severity.
The study also concluded that those who do not display antidrug antibodies in the first 24 weeks are not likely to develop it in the future. If ADAs are not present, dose shortening can be useful. Once ADAs are displayed, however, dose shortening is not efficacious.